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Todd R. Vogel, MD, Larry E. Shindelman, MD, Gary B. Nackman, MD, and Alan M. Graham, MD,
New Brunswick, NJ
Objective: To evaluate the performance and identify predictors of outcome after the use of self-expanding nitinol stents in
the treatment of femoropopliteal arterial occlusive disease.
Methods: A retrospective analysis of a prospectively collected database was performed. Outcomes of patients who
underwent placement of a nitinol stent in the femoral or above-knee popliteal arteries between 1999 and 2002 were
studied. Patency, limb salvage, and patient survival were determined by Kaplan-Meier estimation and intergroup
comparisons by log-rank test and Cox proportional hazards model. To define individual factors associated with clinical
outcomes, stepwise regression analysis was performed.
Results: A total of 41 patients (mean age, 70  10 years; gender, 26 men and 15 women) underwent percutaneous
placement of nitinol stents. Limb salvage was the indication for intervention in 68% of patients. Diabetes was present in
54%, and 36% had end-stage renal disease. Nitinol stents were placed in the superficial femoral (35 patients) or the
above-knee popliteal (6 patients) arteries. The mean postprocedural increase in ankle-brachial index was 0.32 0.19. The
6-month, 1-year, and 2-year primary patency and limb-salvage rates were 95%, 84%, and 84%, and 92%, 89%, and 89%,
respectively. Major amputations occurred only in patients undergoing limb-salvage procedures presenting with major
tissue loss. No statistically significant differences in patency were seen with regard to diabetes, end-stage renal disease,
runoff score, length of vessel stented (median, 80 mm), hypertension, or smoking.
Conclusions: Our initial experience with self-expanding nitinol stents for femoropopliteal occlusive disease appears to
demonstrate acceptable patency and limb-salvage rates at these early time points. Further evaluation of clinical outcome
with these devices in this and larger groups of patients is warranted. (J Vasc Surg 2003;38:1178-84.)
Endovascular therapies are increasingly being applied
in the management of infrainguinal ischemia. Reasons that
have influenced the greater use of endovascular therapy
within the superficial femoral artery (SFA) and the popliteal
artery include the potential for decreased operative morbid-
ity and mortality, decreased length of stay, and decreased
wound complications. Percutaneous transluminal angio-
plasty is an accepted technique for the treatment of femo-
ropopliteal occlusive disease, but the long-term results are
considered suboptimal.1-5
Immediate technical failure of balloon angioplasty can
occur and is associated with eccentric lesions, longer le-
sions, and calcification.4,5 There are increasing reports in
the literature of the use of stents in the femoropopliteal
arteries. Stents are used both selectively, after a suboptimal
technical result following angioplasty, or primarily. The
patency of stents within the femoropopliteal arteries has
been debated, with poor clinical outcome seen in a variety
of studies.6-9 Most published studies reporting femoropop-
liteal stenting have utilized balloon expandable stents. Few
published series document the use of nickel-titanium alloy
(nitinol) stents in the femoral and popliteal arteries.10-13
The use of nitinol in the femoropopliteal arteries offers the
theoretical possibility of superior patency because of its
self-expandable form, continued radial force, and ability for
crush recovery. The purpose of this article is to review our
experience with nitinol self-expanding stents and to evalu-
ate their effectiveness for primary stent placement in the
femoropopliteal arteries.
METHODS
Patients. Since 1999, all patients undergoing surgery
by the Division of Vascular Surgery at the University of
Medicine and Dentistry of New Jersey–Robert Wood
Johnson Medical School at the Robert Wood Johnson
University Hospital have been prospectively entered into a
database. We identified all patients with symptomatic fem-
oropopliteal disease classified by clinical categories for
chronic limb ischemia14 who underwent treatment with
the use of self-expanding nitinol stents. Patients were ex-
cluded if they had failed previous ipsilateral stent or graft
placement, significant inflow lesions, or contraindication to
contrast injection. We performed a retrospective review of a
prospectively collected database. Patients were analyzed on
the basis of the procedure performed as identified from our
database. We did not collect or review information about
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angiograms performed on patients who were not amenable
to endovascular therapy.
Pretreatment evaluation. All patients had preopera-
tive measurement of their ankle-brachial index (ABI). All
patients were categorized with the use of the clinical criteria
for categories of limb ischemia.14 Patient risk factors and
comorbidities, including age, gender, smoking history, di-
abetes (DM), hypertension, and end-stage renal disease
(ESRD), were determined according to Society of Vascular
Surgery reporting standards.14-16 Diagnostic angiography
was performed by using an OEC 9800 C-arm. Percentage
of stenosis was identified from the pretreatment angiogram.
Runoff score was calculated as described in the Starr Reg-
istry.5 Each tibial vessel was assigned a score (0  50%
stenosis, 1 50%-99% stenosis, 2 occluded), the sum of
which is the total runoff score (0-6).
Treatment description. All interventions were per-
formed from a contralateral approach by using local anes-
thesia and conscious-sedation, by one surgeon (L.E.S.).
Because of the lack of a clear consensus with regard to the
management of TransAtlantic Inter-Society Consensus
(TASC) type B and C lesions, all lesions were primarily
stented in this series with nitinol stents. A micropuncture
technique was used for placement of a 5F sheath. An
aortogram and roadmap masks were created. A 7F catheter
was subsequently placed into the contralateral position for
stent deployment. Under roadmap guidance lesions were
crossed by using a 0.18 wire. The patients were anticoagu-
lated with heparin. Patients underwent selective prestent
angioplasty only to allow for passage of the nitinol stent if it
would not pass without angioplasty. The stents used were
self-expanding nitinol stents (SMART or Precise; Cordis;
Johnson & Johnson Company, Warren, NJ). Stent diame-
ter was oversized by 20% of the normal artery diameter. All
patients underwent poststent deployment angioplasty that
was performed within the confines of the stent to remove
any residual stenosis. Stents were dilated by using angio-
plasty to the approximate normal diameter of the artery.
Care was taken to keep the balloon dilatation within the
confines of the stented artery. Lesions adjacent to the most
severe stenosis targeted for treatment were treated so that
no residual stenosis remained that compromised 30% of the
luminal diameter. Stents were placed covering all athero-
sclerotic irregularities that compromised 30% of the luminal
diameter in the area of the target stenosis. Completion
angiography was performed on all patients. All patients
were placed on clopidogrel 75mg orally immediately after
the procedure and were to remain on this regimen
indefinitely.
Posttreatment evaluation. Patients were followed af-
ter the procedure to determine change in the clinical symp-
toms and assessment by hemodynamic improvement in the
ABI at 1- to 3-month intervals after the procedure to
6-month intervals after the initial 3-month period. The end
points of the study were primary and primary-assisted pa-
tency, limb salvage, patient survival, length of stay, and
changes in clinical status. An intervention was considered
clinically successful when there was improvement of at least
one clinical category and an improvement in the ABI
greater than 0.15.14-16 Changes in the condition of the
affected extremity were categorized on a scale of3 to3,
defined by changes in clinical status.14-16 Preprocedure and
postprocedure duplex evaluations were not used in this
series.
Statistical analysis. Patient survival, graft patency,
and limb salvage were determined by Kaplan-Meier esti-
mates and were reported as per the reporting standards
defined by Rutherford.14 To identify factors affecting clin-
ical outcome, univariate analysis was performed by log-rank
and Cox proportional hazard model. Statistical significance
was reported as P  .05. To define individual factors
associated with clinical outcomes, stepwise regression anal-
ysis was performed.
RESULTS
Demographics and indications
A total of 41 patients underwent percutaneous place-
ment of nitinol stents (Table I). Diabetes was present in
54%, and 36% had end-stage renal disease. The indication
for femoropopliteal stenting was limb salvage in 68% of
patients. The mean preintervention category of chronic
limb ischemia was 4  0.16. The mean lesion length was
6.69 cm, with a range between 2.8 cm and 16.8 cm; 66% of
patients had an ABI of less than 0.6. The anatomic features
of the lesions, the runoff scores, the length of the lesions,
and the TASC morphologic stratification of femoropopli-
teal were calculated from the diagnostic angiogram (Table
II). No patients with occlusions or TASC D lesions were
included in this study.
Clinical results
Primary clinical results. Stent placement created an
initial change in the resting ABI from 0.49  0.19 to 0.81
 0.24 (P  .01). The mean clinical improvement score
after percutaneous intervention was2 0.22 (Table III).
Table I. Patient demographics
Patient demographics
Mean age  SEM 70.4  1.5
Gender (male:female) 26:15 63%:37%
Smokers 34 83%
ESRD 15 37%
Diabetes mellitus 22 54%
Clinical category
1 mild claudication 0
2 moderate claudication 0
3 severe claudication 13 32%
4 rest pain 9 22%
5 minor tissue loss 14 34%
6 major tissue loss 5 12%
PreProcedural ABI
0.30 7 17%
0.40 6 15%
0.50 9 22%
0.60 5 12%
0.70 8 20%
0.80 3 7%
0.90 3 7%
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Patency. The 6-month, 1-year, and 2-year primary
patency rates were 95%, 84%, and 84%, respectively, by
Kaplan-Meier estimation (Fig 1). A single patient during
the study period underwent a repeat angioplasty for in-
stent restenosis detected by a decrease in the ABI and
return of claudication. The primary assisted patency was
95%, 90%, and 90% at 6 months, 1 year, and 2 years,
respectively. No statistically significant differences in pa-
tency were seen with regard to diabetes, end-stage renal
disease, hypertension, age, runoff score, or smoking by
log-rank or Cox proportional hazards analysis.
Survival. Survival was 94%, 89%, and 89% at 6
months, 1 year, and 2 years, respectively (Fig 2). No
statistically significant differences in survival were seen with
regard to diabetes, end-stage renal disease, hypertension,
age, runoff score, or smoking by log-rank or Cox propor-
tional hazards analysis.
Length of stay. The mean length of stay after the
procedure was 5 1.9 days. The median length of stay was
1 day (range, 0-62). Excluding two outliers (54 and 62
days), the mean length of stay decreased to 2.3 0.57 days;
37% of the patients went home the same day as the proce-
dure and 22% of the patients were discharged 1 day after the
procedure. We performed a forward stepwise regression
analysis to identify factors associated with increased length
of stay. We hypothesized that the presence of minor or
major tissue loss as indication for procedure, diabetes,
end-stage renal disease, and increasing age would be factors
associated with increased length of stay. This model iden-
tified that the presence of ESRD and decreased age were
the only independent factors (P  .01). When the two
length of stay outliers were excluded from the analysis,
ESRD and DM were found to be significant independent
factors influencing the length of stay (P .01). The results
are shown in Table IV (online only).
Complications. Complications occurred in 7 of 41
(17%) patients. No procedural-related deaths occurred.
One arterial outflow thrombosis occurred within 24 hours
of stent placement after previous tissue plasminogen acti-
vator (tPA) therapy of the outflow vessels. Further descrip-
tion of this patient is described in the following “Limb
salvage” section. One in-stent stenosis within 30 days of the
procedure was identified. This lesion was amenable to
repeat in-stent angioplasty with no adverse sequelae and is
accounted for in the primary assisted patency calculation.
Minor complications included 2 groin hematomas, 1 pseu-
doaneurysm, and 1 arrhythmia, and one patient developed
a myocardial infarction with no hemodynamic conse-
quences. Periprocedural myocardial infarction was classi-
fied as a minor complication as per the reporting standards.
The periprocedural myocardial infarction was hemodynam-
ically insignificant, was noted through a rise in troponin
without significant electrocardiogram changes, and had no
effect on patient quality of life or length of stay for the
patient.
Limb salvage. Limb salvage was 92%, 89%, and 89% at
6 months, 1 year, and 2 years, respectively, for the entire
Table II. Anatomic and angiographic lesion
characteristics
Anatomic/angiographic
characteristics N (%)
Site of Involvement
SFA 35 (85)
Popliteal 6 (15)
Lesion length
2 cm 0
2 cm to 5 cm 11 (27)
5 cm to 10 cm 26 (63)
10 cm 4 (10)
TASC morphologic grading
Type A 0
Type B 37 (90)
Type C 4 (10)
Length stented
Mean 96  7.04 mm
Range 40-240 mm
Runoff score
0 7
1 2
2 3
3 7
4 11
5 4
6 7
Table III. Clinical status after intervention
Clinical limb status after
stenting
No. of limbs
(%)
3 marked improvement 12 (29)
2 moderate improvement 22 (54)
1 mild improvement 3 (7)
0 no change 3 (7)
1 mild worsening 1 (2)
2 moderate worsening 0
3 marked worsening 0
Fig 1. Primary patency was determined by Kaplan-Meier estima-
tion. All standard errors are less than 0.10. The number of patients
at risk of each interval is recorded.
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cohort. Limb salvage for those patients in whom proce-
dures were performed for claudication, rest pain, and minor
tissue loss was 100% during the study. Major amputations
occurred only in patients with major tissue loss undergoing
limb-salvage procedures. Limb salvage for patients with
category 6 of chronic limb ischemia was extremely poor
(Fig 3). Of the five patients in this subgroup, four lost their
legs within 3 months of intervention. The mean runoff
score of the amputated patients was 5, suggesting multi-
level disease and extremely poor outflow with a diseased
single tibial vessel to the foot. The mean postprocedural
ABI was 0.40  0.17 for patients with category 6 disease,
which was significantly worse than a mean of 0.86  0.03
for all other patients (P .05 by analysis of variance). Four
below-the-knee amputations occurred despite three patent
stents. Of the three patients who underwent amputation
despite a patent stent, two patients benefited with a change
of the level of amputation required from an above-the-knee
amputation to a below-the-knee amputation.
One amputation occurred in a patient despite a patent
stent because of progression of gangrene and worsening
infection. A second patient with a history of chronic limb
ischemia presented with increased pain in the calf and was
found to have a thrombosed femoropopliteal artery and
thrombosed outflow. This patient initially received throm-
bolytic therapy with tPA. Following thrombolytic therapy
there appeared to be two-vessel runoff to the lower extrem-
ity. A distal SFA lesion was noted and a stent was placed.
There was initial hemodynamic success, but the patient lost
pedal Doppler signals within 24 hours. Repeat angiography
revealed re-thrombosis of the outflow, and the patient
subsequently underwent a below-the-knee amputation.
Two other below-the-knee amputations occurred in
patients with end-stage renal disease and extensive gan-
grene at the time of procedure. Each of these patients had
runoff scores of 5. Femoropopliteal stenting was chosen
rather than surgical bypass because they were both poor
operative candidates with severe coronary arterial occlusive
disease, had poor life expectancy, and had insufficient vein
for surgical bypass. The first patient with end-stage renal
disease was found to have no increase of the ABI after the
procedure. The patient had an occlusion of the tibial pero-
neal trunk and a stenosis greater than 50% of the anterior
tibial artery. This patient would have required a femoral-
to–dorsalis pedis bypass with nonautogenous conduit be-
cause of lack of saphenous or alternative autologous vein
conduit. On the basis of the comorbidities of the patient,
amputation was chosen.
The second patient with end-stage renal disease also
had an occluded anterior tibial artery and posterior tibial
artery with a stenosis greater than 50% the peroneal artery.
This patient also failed to show a significant increase in his
postprocedure ABI. The patient would have required a
femoral-to-midperoneal bypass with prosthetic material.
This patient proceeded to have progression of gangrene,
and a follow-up angiogram revealed a patent stent with
thrombosis of the peroneal artery. Thrombolysis with tPA
was unsuccessfully attempted, and the patient eventually
underwent a below-the-knee amputation.
DISCUSSION
Endovascular treatment of atherosclerotic disease of
the femoropopliteal arteries is a controversial subject with a
large range of outcomes reported in the literature. The
reported 1-year patency rates for femoropopliteal stent
placement using stents not constructed from nitinol varies
between 59% and 81%.2,6-9,17,18 Our series with nitinol
stents demonstrated a 1-year primary patency, and primary
assisted patency rates were 84% and 90%, respectively. Most
of the studies in the literature reflect a large variety of stents
used within the femoropopliteal arteries that were not
constructed from nitinol. Strecker et al6 reported a 1-year
patency rate of 59% with the use of a balloon-expandable
tantalum stent. The use of the Palmaz (Cordis, Johnson &
Fig 2. Survival was determined by Kaplan-Meier estimation. All
standard errors are less than 0.10. The number of patients at risk
for each interval is recorded.
Fig 3. Limb salvage by clinical category was determined by
Kaplan-Meier estimation. All standard errors are less than 0.10.
The difference between groups was significant (P  .003, log
rank).
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Johnson) stent has been shown to have a 1-year patency
rate of 74% in one study and 81% in another.7,8 The
Wallstent (Boston Scientific Vascular, Boston, Mass) was
shown in a multicenter trial to have a 1-year patency of
61%.9
There are few series in the literature which report the
primary use of nitinol stents for femoropopliteal le-
sions.10-13 Series reporting the use of nitinol in the femoral
and popliteal arteries report primary patency similar to
those found in our series (85%-87%).10-13 The use of
self-expanding nitinol for stent construction might play a
role in maintaining patency. Nitinol stents exert a constant
radial force on the arterial surface and plaque, are crush
recoverable, and are flexible when in the lower extremity.
The use of nitinol could allow for a higher patency than
seen with other stent material described in the literature,
but this needs to be further defined.
We performed systematic use of nitinol stents for all
femoropopliteal lesions in the study period. Several studies
have shown no advantage to the systematic use of stents in
the femoropopliteal arteries.2,19 Becquemin et al19 re-
ported in a recent publication the cumulative “survival free
of vascular critical events” by using angioplasty versus se-
lective stent placement with Palmaz (Cordis, Johnson &
Johnson) stents to be 74% and 71% at 1 year and 52% and
44% at 2 years, respectively. Becquemin et al19 found no
justification of systematic stent placement in the superficial
femoral artery. To our knowledge, no prospective random-
ized studies have been performed comparing systematic
versus selective stent placement using nitinol stents.
We also believe the technique used in the placement of
the stent is critical to successful outcomes. Angioplasty
prior to nitinol stent deployment occurred only if the
delivery system would not cross the lesion. After deploy-
ment of the nitinol stent postdeployment balloon dilatation
occurred within the confines of the stent. This technique
allows for a controlled dissection plane after angioplasty.
Limited angioplasty within the confines of the nitinol stent
might lead to decreased arterial trauma, decreased intimal
hyperplasia, and decreased in-stent stenosis.
Patient selection plays an important role in outcomes of
percutaneous interventions. As procedures become less
invasive, there is the tendency to treat sicker patients who
might have undergone a primary amputation and not limb
salvage. Our experience shows that most patients who had
femoropopliteal stenting with severe tissue loss and poor
outflow eventually required an amputation. This failure is
likely due to multilevel disease in this subset of patients and
poor postoperative revascularization with femoropopliteal
stent placement alone. All amputations occurred in patients
with severe tissue loss and a runoff score of 5. One patient
required amputation for control of gangrene and sepsis
despite a patent stent. Another patient presented with
thrombosed outflow, which remained thrombosed after
tPA therapy, and the patient subsequently required an
amputation. Two other amputations occurred in patients
with very severe category 6 tissue loss, diabetes, and out-
flow scores of 5. Patients with category 6 tissue loss and
runoff scores greater than 5 had an amputation rate of 80%,
although the level of amputation was changed from an
above-the-knee amputation to a below-the-knee amputa-
tion in two of the four amputations. The hemodynamic
results of this subgroup suggest significant residual isch-
emia was still present. No further vascular reconstructive
procedures were considered appropriate for these patients.
Therefore, femoropopliteal stenting alone was not ade-
quate revascularization for limb salvage and would not be
recommended as primary therapy in patients with category
6 tissue loss and poor runoff scores.
Stepwise regression analysis demonstrated that patients
with end-stage renal disease and a decreased age were
associated with increased lengths of stay. When two outliers
for length of stay were excluded from the group, DM was
also found to be associated with increased lengths of stay.
There was no statistically significant difference in the eval-
uated risk factors for the younger and older patient groups.
One of the weaknesses of this study is that it is a small
retrospective series with a short mean follow-up of 11
months. The study size and limited time of follow-up
would lead to caution in creating absolute recommenda-
tions. This study uses clinical indicators, pulse volume
recording, and ABI results to assess patency. Surveillance
duplex was not used, and angiography was performed only
on the basis of clinical and minimally invasive tests.
The follow-up without the use of postoperative duplex
is a potential limitation of the study. As has been reported,
a stenosis of greater than 50% can be distinguished from
minor stenosis and more precise definition of the degree of
narrowing is more difficult.20 This tool will be valuable for
future follow-up and might have shown a higher percent-
age of stenosis or failure than we detected in our study by
using clinical parameters alone.
This study suggests that femoropopliteal stenting is a
reasonable and safe procedure with good primary and
primary-assisted patency and limb salvage when limited to
patients with claudication or only mild tissue loss. If therapy
for major tissue loss is to be attempted, the hemodynamic
result must be adequate to provide improved blood flow for
healing to occur. The presence of major tissue loss inher-
ently suggests multilevel vascular disease. Because all our
patients in this report had normal inflow, the focus on
femoropopliteal revascularization implies that residual infra-
popliteal occlusive disease was present. If patients were not
surgical candidates for more complete revascularization,
limited intervention was not effective. Larger randomized
studies with duplex assessment and longer follow-up are
needed to assess definitive outcomes and clinical success.
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DISCUSSION
Dr Michael B. Silva, Jr (Lubbock, Tex). Your colleagues and
you are reporting on Dr Shindelman’s placement of nitinol stents
in 41 patients over a 3-year period with a mean follow-up of 11
months. Sixty-eight percent of the patients were treated for limb
salvage and 32% for claudication. Good 1-year and 2-year primary
patency and limb salvage rates were achieved: 84% primary patency
at 1 year and 89% limb salvage at 1 year. But you had six patients
with major tissue loss who were treated with angioplasty and
stenting. In that group the limb loss rate was 80%.
I have a couple of questions for you, the answers to which may
help clarify your message. First, please comment in more detail on
the technical aspects of your procedures, specifically, your routine
choice of the up-and-over approach versus the antegrade femoral
approach. What size system did you use? I notice that you men-
tioned using a .018-inch wire for crossing these lesions. Is this your
routine crossing-wire size?
With an average length of these lesions of 10 cm, with some as
long as 25 cm, multiple stents were probably required for each
patient. How many stents did you end up using per patient?
More importantly, your follow-up was by clinical status and
ankle-brachial indexes. The first evaluation was performed at a 1-
to 3-month postprocedure visit. The second evaluation was 6
months after that. So with a mean follow-up of 11 months, the
average patient had his ankle-brachial index checked twice. Duplex
surveillance of the stented areas was not performed. Do you think
that this practice is sufficient to identify recurrent stenoses within
the stents and the failing endovascular procedure?
Finally, should the patients with major tissue loss have under-
gone more aggressive intervention in an effort to normalize their
infrageniculate pressures? It is unlikely that SFA angioplasty and
stenting alone would improve distal circulation sufficiently to
prevent limb loss in this severely ischemic group. Do you perform
infrapopliteal endovascular intervention in your practice? Would
that have been an alternative for these patients?
I would like to thank the authors for providing me with their
manuscript for advance review. I would like to thank the Society
for the opportunity to participate in this important process and Dr
Graham for enhancing and embracing endovascular management
as an excellent alternative to the ravages of open femoropopliteal
bypass.
Dr Todd R. Vogel. With regard to your first question, the
diagnostic angiography was performed from a 5 French system. At
that time we would switch out, once we had contralateral access,
and use a 7 French system. All the stents were nitinol SMART
stents, so we needed a 7 French delivery system.
With regard to your second question, the average stent length
was approximately 10 cm. The median was 8 cm. So approximately
2 stents were used per patient. And we didn’t really find a differ-
ence in terms of patency compared with studies in terms of our
mean stent length. I went back and looked at several of the
published series on the number of stents and stent length, and we
didn’t really note a difference in terms of our patency versus their
studies.
I agree completely with your analysis of the follow-up, the
clinical series, and the clinical physical exam, as well as ankle-
brachial indexes, which is what was used. There have been several
reports in the literature showing the superiority of duplex surveil-
lance. We agree, I think, that the next study we produce will
probably use that for follow-up, although we did follow the
Rutherford criteria for outcomes reporting.
JOURNAL OF VASCULAR SURGERY
Volume 38, Number 6 Vogel et al 1183
